Joint Formulary & PAD

House dust mites allergen extract - Allergic rhinitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral lyophilisates
Associated Icons :
Restrictions / Comments :
Important

As per NICE TA - for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years

To be initiated at specialist allergy clinics only (locally at ASPH & RSFT) with at least 3 months prescribing before transfer to primary care.

 

Status 2

Red
Formulations :
  • Oral lyophilisates
Associated Icons :
Restrictions / Comments :
Important

Aged 5 to 12 years. Paediatric specialist only

PAD Profile

ChemicalSubstance :
House dust mites allergen extract
Indication :
Allergic rhinitis
Group Name :
Keywords :
allergic disorders, dust mite allergy, allergens, allergen therapy, hyposensitising agents,
Brand Names Include :
Acarizax
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
2

Committee Recommendations (2)

03 Oct 25 - RSFT DTC

Use in 5 years and up approved

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves Acarizax (12 SQ-HDM SLIT) for treating allergic rhinitis caused by house dust mites in line with NICE TA1045.

A BLUE (with specialist initiation) traffic light status has been agreed with at least 3 months prescribing by the specialist team to enable review and confirmation of clinical benefit, prior to transfer of care to Primary Care